美军人员接种mRNA新冠疫苗后发生心肌炎的病例系列
该回顾性病例系列纳入2021年1月至4月美军卫生系统中接种mRNA新冠疫苗后诊断为临床心肌炎的患者,共23例男性(中位年龄25岁),多在第二剂后4天内出现明显胸痛、心肌肌钙蛋白显著升高,8例急性期心脏磁共振均符合心肌炎,均经短暂支持治疗后恢复或好转;观察病例数虽少,但男性军人第二剂后心肌炎例数高于预期。
要点
- 接种mRNA新冠疫苗后4天内出现明显胸痛者应警惕心肌炎。
- 23例均为男性,中位年龄25岁,20例症状始于第二剂后。
- 所有患者心肌肌钙蛋白显著升高,8例急性期心脏磁共振均符合心肌炎。
核心结论
- 在既往健康的军人中,接种mRNA新冠疫苗后出现临床表现相似的心肌炎病例。
- 观察到的病例数虽少,但男性军人第二剂后心肌炎例数高于预期,需进一步监测与评估。
研究设计与样本
- 回顾性病例系列,研究2021年1月至4月美军卫生系统中接种mRNA新冠疫苗后发生心肌炎的患者。
- 纳入接种后因胸痛就诊并随后诊断为临床心肌炎者,且无其他明确病因。
- 暴露为2021年1月1日至4月30日接种mRNA新冠疫苗。
主要发现
- 共23例男性患者(22名现役军人、1名退休人员;中位年龄25岁,范围20-51岁),在接种mRNA新冠疫苗后4天内出现急性明显胸痛。
- 所有军事成员既往健康且体能良好;7例接种BNT162b2-mRNA疫苗,16例接种mRNA-1273疫苗。
- 20例在间隔合适的2剂系列的第二剂后出现症状。
- 所有患者心肌肌钙蛋白水平显著升高;8例急性期心脏磁共振均符合心肌炎临床诊断。
- 其他检查未发现急性COVID-19及其他感染、缺血性损伤或潜在自身免疫性疾病等病因;所有患者接受短暂支持治疗,报告时已恢复或正在恢复。
临床怎么用
- 接种mRNA新冠疫苗后短期内出现明显胸痛者应评估心肌炎可能。
- 对疑似病例应检测心肌肌钙蛋白,必要时行心脏磁共振等检查排除其他病因。
- 多数病例经短暂支持治疗后可恢复或好转。
局限性
- 为回顾性病例系列,观察到的病例数较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Myocarditis has been reported with COVID-19 but is not clearly recognized as a possible adverse event following COVID-19 vaccination. OBJECTIVE: To describe myocarditis presenting after COVID-19 vaccination within the Military Health System. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series studied patients within the US Military Health System who experienced myocarditis after COVID-19 vaccination between January and April 2021. Patients who sought care for chest pain following COVID-19 vaccination and were subsequently diagnosed with clinical myocarditis were included. EXPOSURE: Receipt of a messenger RNA (mRNA) COVID-19 vaccine between January 1 and April 30, 2021. MAIN OUTCOMES AND MEASURES: Clinical diagnosis of myocarditis after COVID-19 vaccination in the absence of other identified causes. RESULTS: A total of 23 male patients (22 currently serving in the military and 1 retiree; median [range] age, 25 [20-51] years) presented with acute onset of marked chest pain within 4 days after receipt of an mRNA COVID-19 vaccine. All military members were previously healthy with a high level of fitness. Seven received the BNT162b2-mRNA vaccine and 16 received the mRNA-1273 vaccine. A total of 20 patients had symptom onset following the second dose of an appropriately spaced 2-dose series. All patients had significantly elevated cardiac troponin levels. Among 8 patients who underwent cardiac magnetic resonance imaging within the acute phase of illness, all had findings consistent with the clinical diagnosis of myocarditis. Additional testing did not identify other etiologies for myocarditis, including acute COVID-19 and other infections, ischemic injury, or underlying autoimmune conditions. All patients received brief supportive care and were recovered or recovering at the time of this report. The military administered more than 2.8 million doses of mRNA COVID-19 vaccine in this period. While the observed number of myocarditis cases was small, the number was higher than expected among male military members after a second vaccine dose. CONCLUSIONS AND RELEVANCE: In this case series, myocarditis occurred in previously healthy military patients with similar clinical presentations following receipt of an mRNA COVID-19 vaccine. Further surveillance and evaluation of this adverse event following immunization is warranted. Potential for rare vaccine-related adverse events must be considered in the context of the well-established risk of morbidity, including cardiac injury, following COVID-19 infection.
引用
- Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021. PMID: 34185045. doi:10.1001/jamacardio.2021.2833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。